JPWO2021077117A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021077117A5
JPWO2021077117A5 JP2022521958A JP2022521958A JPWO2021077117A5 JP WO2021077117 A5 JPWO2021077117 A5 JP WO2021077117A5 JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022521958 A JP2022521958 A JP 2022521958A JP WO2021077117 A5 JPWO2021077117 A5 JP WO2021077117A5
Authority
JP
Japan
Prior art keywords
receptor
chimeric antigen
domain
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552314A (ja
JP7664913B2 (ja
JP2022552314A5 (https=
Publication date
Priority claimed from PCT/US2020/054601 external-priority patent/WO2021071962A1/en
Application filed filed Critical
Priority claimed from PCT/US2020/056387 external-priority patent/WO2021077117A1/en
Publication of JP2022552314A publication Critical patent/JP2022552314A/ja
Publication of JP2022552314A5 publication Critical patent/JP2022552314A5/ja
Publication of JPWO2021077117A5 publication Critical patent/JPWO2021077117A5/ja
Priority to JP2025063708A priority Critical patent/JP2025108510A/ja
Application granted granted Critical
Publication of JP7664913B2 publication Critical patent/JP7664913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521958A 2019-10-17 2020-10-19 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 Active JP7664913B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063708A JP2025108510A (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962916468P 2019-10-17 2019-10-17
US62/916,468 2019-10-17
PCT/US2020/054601 WO2021071962A1 (en) 2019-10-07 2020-10-07 Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
USPCT/US2020/054601 2020-10-07
PCT/US2020/056387 WO2021077117A1 (en) 2019-10-17 2020-10-19 Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063708A Division JP2025108510A (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Publications (4)

Publication Number Publication Date
JP2022552314A JP2022552314A (ja) 2022-12-15
JP2022552314A5 JP2022552314A5 (https=) 2023-10-27
JPWO2021077117A5 true JPWO2021077117A5 (https=) 2023-10-27
JP7664913B2 JP7664913B2 (ja) 2025-04-18

Family

ID=75537569

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521958A Active JP7664913B2 (ja) 2019-10-17 2020-10-19 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用
JP2025063708A Pending JP2025108510A (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063708A Pending JP2025108510A (ja) 2019-10-17 2025-04-08 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用

Country Status (5)

Country Link
US (1) US20240226293A9 (https=)
EP (1) EP4045539A4 (https=)
JP (2) JP7664913B2 (https=)
CN (1) CN114901693A (https=)
WO (1) WO2021077117A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
EP4352519A4 (en) * 2021-05-20 2025-05-14 Synteny Therapeutics, Inc. GENOMIC SAFE HARBORS
JP2024542159A (ja) * 2021-11-04 2024-11-13 アーティバ バイオセラピューティクス インコーポレイテッド Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置
JP2024543024A (ja) * 2021-11-08 2024-11-19 フェイト セラピューティクス，インコーポレイティド 操作されたエフェクター細胞及び固形腫瘍の広範な標的化を増強する方法
CN116103239A (zh) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 工程化免疫细胞及其用途
AU2023206330A1 (en) * 2022-01-11 2024-08-22 Celularity Inc. Cleavage resistant cd16 constructs and uses thereof
EP4504914A4 (en) 2022-04-08 2026-04-29 Fate Therapeutics Inc Cells having solid tumor targeting backbone and use thereof
CA3247010A1 (en) 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
CN120035658A (zh) * 2022-12-27 2025-05-23 恺兴生命科技(上海)有限公司 Nkg2d工程化细胞及其组合物
CN116445414B (zh) * 2023-03-03 2025-07-08 广州瑞臻再生医学科技有限公司 基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用
CN117285651B (zh) * 2023-09-27 2025-06-06 中国医学科学院北京协和医院 靶向c-MET的嵌合抗原受体、CAR-M及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
JP6928604B2 (ja) * 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3003152A1 (en) * 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2018132506A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
US20210015859A1 (en) * 2017-12-08 2021-01-21 Fate Therapeutics, Inc. IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
CA3083779A1 (en) * 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
JP7575271B2 (ja) * 2018-03-29 2024-10-29 フェイト セラピューティクス，インコーポレイテッド 操作された免疫エフェクター細胞およびその使用
KR20220165254A (ko) * 2020-03-26 2022-12-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Cd28h 도메인을 함유하는 키메라 항원 수용체 및 그 사용 방법

Similar Documents

Publication Publication Date Title
JPWO2021077117A5 (https=)
JP2021505131A5 (https=)
JPWO2021071962A5 (https=)
Kloess et al. CAR-expressing natural killer cells for cancer retargeting
JP2022176327A (ja) タグ化キメラエフェクター分子およびそのレセプター
JP2024518011A (ja) 多様な免疫細胞のための単鎖および多鎖合成抗原受容体
Budde et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma
JP2021519061A5 (https=)
Hombach et al. Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
JP7566628B2 (ja) キメラ抗原受容体を発現する免疫細胞
JP2018532432A5 (https=)
JP2021536265A5 (https=)
CN106574246A (zh) 用于细胞免疫治疗的方法和组合物
US12187776B2 (en) Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor
RU2013147157A (ru) Способ и композиции для клеточной иммунотерапии
JP2019531328A5 (https=)
TW201930342A (zh) 包含nkg2d結構域的多特異性嵌合受體及其使用方法
JPWO2019191495A5 (https=)
WO2020057641A1 (zh) 表达有趋化因子的细胞及用途
JPWO2020210398A5 (https=)
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도
JPWO2022178367A5 (https=)
JPWO2021062281A5 (https=)
Faitschuk et al. A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv